Get the Stockscreener App
5.45
3.22%
0.17
Inovio Pharmaceuticals Inc stock is traded at $5.45, with a volume of 231.81K.
It is up +3.22% in the last 24 hours and down -3.02% over the past month.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
See More
Previous Close:
$5.28
Open:
$5.3
24h Volume:
231.81K
Relative Volume:
0.80
Market Cap:
$144.36M
Revenue:
$832.00K
Net Income/Loss:
$-135.12M
P/E Ratio:
-8.3846
EPS:
-0.65
Net Cash Flow:
$-124.69M
1W Performance:
-2.68%
1M Performance:
-3.02%
6M Performance:
-52.98%
1Y Performance:
+21.34%
1-Day Range:
$5.30
$5.5599
1-Week Range:
$5.25
$5.80
52-Week Range:
$3.888
$14.75
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
Name
Inovio Pharmaceuticals Inc
Sector
Industry
Phone
(858) 410-3134
Address
6769 MESA RIDGE RD., SAN DIEGO, PA
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-09-22 | Downgrade | Maxim Group | Buy → Hold |
| Nov-01-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-19-22 | Resumed | RBC Capital Mkts | Sector Perform |
| May-11-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Dec-29-21 | Resumed | Jefferies | Hold |
| Sep-10-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-24-21 | Initiated | Jefferies | Hold |
| Mar-23-21 | Initiated | BofA Securities | Neutral |
| Feb-12-21 | Initiated | Oppenheimer | Outperform |
| Nov-17-20 | Downgrade | ROTH Capital | Neutral → Sell |
| Nov-10-20 | Upgrade | ROTH Capital | Sell → Neutral |
| Sep-28-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-28-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-01-20 | Downgrade | Maxim Group | Buy → Hold |
| Jul-01-20 | Downgrade | ROTH Capital | Neutral → Sell |
| Jun-29-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-26-20 | Downgrade | Stifel | Buy → Hold |
| May-21-20 | Initiated | The Benchmark Company | Buy |
| Apr-30-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Mar-13-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-13-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-19-19 | Initiated | ROTH Capital | Buy |
| Feb-15-18 | Reiterated | Maxim Group | Buy |
| Oct-18-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-06-17 | Initiated | Citigroup | Buy |
| Jun-08-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| May-24-17 | Reiterated | Maxim Group | Buy |
| Mar-16-17 | Upgrade | Maxim Group | Hold → Buy |
| Mar-16-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
View All
Inovio Pharmaceuticals Inc Stock (INO) Latest News
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Inovio Pharmaceuticals Inc. stock remains steady Wednesday, still outperforms market - MarketWatch
Inovio Pharmaceuticals (LTS:0A43) Probability of Financial Distress (%) : 0.27% (As of Oct. 30, 2024) - GuruFocus.com
Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Inovio Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Brokerages Set Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Target Price at $43.80 - MarketBeat
INOVIO Announces New Data at Scientific Conferences for Lead Candidate, INO-3107, as a Potential Treatment for RRP - StockTitan
Indo-Asian News Service - IANS India Pvt Ltd
Global DNA Nanotechnology Market Future Market Projections: - openPR
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Short Interest Update - MarketBeat
Inovio Pharmaceuticals (LTS:0A43) Change In Prepaid Assets : $-2.12 Mil (TTM As of Jun. 2024) - GuruFocus.com
Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Inovio Pharmaceuticals, Inc. Reports Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2011; Promotes Niranjan Y. Sardesai as Chief Operating Officer from Senior Vice President Research and Development - Marketscreener.com
Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Covid-19 Vaccine Market Industry Survey Research Report 2032 – Top Player as Inovio Pharmaceuticals, Takis Biotech (Evvivax), Zydus Cadila, Codagenix – Cauverynews - Cauverynews
Inovio (INO) Surges 6.8%: Is This an Indication of Further Gains? - Yahoo Finance
Inovio Pharmaceuticals, Inc. Announces Leadership Appointments - Marketscreener.com
INOVIO Announces Equity Grants for New Employees Under 2022 Inducement Plan - MSN
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
The Analyst Verdict: Inovio Pharmaceuticals In The Eyes Of 4 Experts - Benzinga
Inovio Pharmaceuticals (NASDAQ:INO) Price Target Lowered to $7.00 at Royal Bank of Canada - MarketBeat
INOVIO Reports Inducement Grants Under Inducement Plan - Marketscreener.com
INOVIO to Present at Upcoming Scientific Conferences - Marketscreener.com
Inovio Pharmaceuticals: Takes Another Torpedo But Keeps On Sailing - Seeking Alpha
Inovio Pharmaceuticals' SWOT analysis: stock faces challenges amid pipeline potential - Investing.com
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives $44.00 Average PT from Analysts - MarketBeat
Inari medical director Hoffman sells over $1.8m in company stock - Investing.com
Inhibrx, Inc. (NASDAQ:INBX) Short Interest Update - MarketBeat
INVO Bioscience (NASDAQ:INVO) Stock Price Down 1.7% - Defense World
INOVIO to Present at Upcoming Scientific Conference - Lelezard
Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Viking Therapeutics: A Bad Result for Roche's Weight-Management Pill Is Great News for Oral VK2735 - sharewise
Page 2 | INOVIO PHARMACEUTICALS INC Trade Ideas — GETTEX:GBMB - TradingView
Inovio Pharmaceuticals Inc. stock rises Wednesday, still underperforms market - MarketWatch
Inovio Pharmaceuticals Inc. stock rises Tuesday, still underperforms market - MarketWatch
Inovio Pharmaceuticals Inc Stock (INO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):